Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yeong Ok Baik"'
Autor:
Jonathan F. Lovell, Kazutoyo Miura, Yeong Ok Baik, Chankyu Lee, Jeong-Yoon Lee, Young-Shin Park, Ingi Hong, Jung Hyuk Lee, Taewoo Kim, Sang Hwan Seo, Jae-Ouk Kim, Manki Song, Chung-Jong Kim, Jae-Ki Choi, Jieun Kim, Eun Ju Choo, Jung-Hyun Choi
Publikováno v:
International Journal of Infectious Diseases, Vol 138, Iss , Pp 73-80 (2024)
Objective: EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. T
Externí odkaz:
https://doaj.org/article/92e258add5c642e19060a10330ea19f8
Autor:
Jonathan F. Lovell, Yeong Ok Baik, Seuk Keun Choi, Chankyu Lee, Jeong-Yoon Lee, Kazutoyo Miura, Wei-Chiao Huang, Young-Shin Park, Sun-Je Woo, Sang Hwan Seo, Jae-Ouk Kim, Manki Song, Chung-Jong Kim, Jae-Ki Choi, Jieun Kim, Eun Ju Choo, Jung-Hyun Choi
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract Background Numerous vaccine strategies are being advanced to control SARS-CoV-2, the cause of the COVID-19 pandemic. EuCorVac-19 (ECV19) is a recombinant protein nanoparticle vaccine that displays the SARS-CoV-2 receptor-binding domain (RBD)
Externí odkaz:
https://doaj.org/article/751995d68b8d49d3808a9e447b241469
Autor:
Chankyu Lee, Hee Jin Chun, Minchul Park, Rock Ki Kim, Yoon Hee Whang, Seuk Keun Choi, Yeong Ok Baik, Sung Soo Park, Inhwan Lee
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 8 (2020)
Streptococcus pneumoniae is the causative agent of many diseases, most notably pneumonia. Most of the currently used vaccines to protect against this pathogen employ pneumococcal capsular polysaccharides (CPSs) as antigens, but purifying CPS of suffi
Externí odkaz:
https://doaj.org/article/64040765039e46f594eae47f97441515
Autor:
Yoon Hee Whang, Soo Kyung Kim, Hyeseon Yoon, Seuk Keun Choi, Yeong Ok Baik, Chankyu Lee, Inhwan Lee
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0243909 (2020)
Glycoconjugate vaccines are vaccines in which a bacterial polysaccharide antigen is conjugated to a carrier protein to enhance immunogenicity by promoting T cell-dependent immune response. However, the free (unreacted) polysaccharides remaining after
Externí odkaz:
https://doaj.org/article/f580eca06e6d416bbf5f3f5cd9711db4
Autor:
Yeong Ok Baik, Youngjin Lee, Chankyu Lee, Soo Kyung Kim, Jooyoung Park, Meixiang Sun, DaYe Jung, Jin Young Jang, Tae Jun Yong, Jeong Woo Park, Sungho Jeong, Suwon Lim, Seung Hyun Han, Seuk Keun Choi
Publikováno v:
Vaccine. 41:1753-1759
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6ac5b5b8dbfe1205cb486c01f2a6162
https://doi.org/10.1016/j.vaccine.2022.12.007
https://doi.org/10.1016/j.vaccine.2022.12.007
Autor:
Seuk Keun Choi, Yeong Ok Baik, Youngjin Lee, Chankyu Lee, Soo Kyung Kim, Jooyoung Park, Meixiang Sun, DaYe Jung, Jin Young Jang, Tae Jun Yong, Jeong Woo Park, Sungho Jeong, Suwon Lim, Seung Hyun Han
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::422f086fbf8c61e86a307a740ff6bfe4
https://doi.org/10.2139/ssrn.4229865
https://doi.org/10.2139/ssrn.4229865
Autor:
Yeong Ok Baik, Il Nam Oh, Chankyu Lee, Chan Wha Kim, Hyeseon Yoon, Seuk Keun Choi, Dajung Yu, Soo-Kyung Kim
Publikováno v:
Vaccine. 39(19)
An injectable typhoid conjugate vaccine (TCV) provides longer-lasting protection, requires fewer doses, and is suitable for children aged >2 years. In addition, TCV is preferred at most ages owing to its improved immunological properties as it overco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::948c388478cbca33fbe88618c5354b44
https://pubmed.ncbi.nlm.nih.gov/33849723
https://pubmed.ncbi.nlm.nih.gov/33849723
Autor:
Han Wool Kim, Robert L. Burton, Hun Kim, Kyung Hyo Kim, Julie M. Skinner, Kun Young Ku, Sun Jin Kim, Moon H. Nahm, Jihye Seo, Seuk Keun Choi, Soyoung Lee, Jee hyun Seok, Jinfu Xie, Yeong Ok Baik, Sejong Bae, Debra Mcguinness
Publikováno v:
Vaccine
Pneumococcal conjugate vaccines (PCVs) have been effective in reducing the disease burden caused by Streptococcus pneumoniae. The first licensed PCV (PCV7) was composed of capsular polysaccharides from seven serotypes. This was followed by PCV10, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c9c1e6f57e721400e120979abefc6e7
https://pubmed.ncbi.nlm.nih.gov/33162203
https://pubmed.ncbi.nlm.nih.gov/33162203
Autor:
Seuk Keun Choi, Jang Hee Hong, Jae Seung Yang, Yeong Ok Baik, JaeWoo Kim, Ick Young Kim, Chan Wha Kim
Publikováno v:
Journal of Korean Medical Science
To the Editor: We found errors in our published article: J Korean Med Sci 2014; 29: 494-501. As two of authors, Young Ok Baik and Seuk Keun Choi belong to Department of Biotechnology, Korea University as well as EuBiologics Co., Ltd, the affiliated i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3abb116cac4817b11b0a8c15fa5fef9b
http://europepmc.org/articles/PMC4129216
http://europepmc.org/articles/PMC4129216